Skip to main content

Advertisement

SpringerLink
Log in

The emerging role of the selective A2A agonist in pharmacologic stress testing

  • Review Article
  • Published:
Journal of Nuclear Cardiology Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1

References

  1. Miyamoto MI, Vernotico SL, Majmundar M, Thomas GS. Pharmacologic stress myocardial perfusion imaging: A practice approach. J Nuc Cardiol 2007;14:250-5

    Article  Google Scholar 

  2. Cerqueira MD, Verani MS, Schwaiger M, Heo J, Iskandrian AS. Safety profile of adenosine stress perfusion imaging: Results of the Adenoscan Multicenter Trial Registry. JACC 1994;23(2):384-9

    CAS  PubMed  Google Scholar 

  3. Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC, et al. Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: Results of the ADVANCE phase 3 multicenter international trial. J Nuc Cardiol 2007;14:645-58

    Article  Google Scholar 

  4. Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE. Effects of age, gender, obesity and diabetes on the efficacy and safety of the selective A2A agonist, regadenoson versus adenosine in myocardial perfusion imaging: Integrated ADVANCE-MPI trial results. JACC Imaging 2008;1:307-16

    Article  Google Scholar 

  5. Mahmarian JJ, Cerqueira MD, Iskandrian AE, Bateman TM, Thomas GS, Hendel RC, et al. Regadenoson induces comparable left ventricular perfusion defects as adenosine: A quantitative analysis from the advance MPI 2 trial. JACC Imaging 2009;2:959-68

    Article  Google Scholar 

  6. www.lexascan.com/home.php. Accessed February 24, 2010

  7. Mekkaoui C, Jadbabaie F, Dione DP, Meoli DF, Purushothaman K, Belardinelli L, et al. Effects of adenosine and a selective A2A adenosine receptor agonist on hemodynamic and thallium-201 and technetium-99m-SestaMIBI biodistribution and kinetics. JACC Imaging 2009;2:1198-208

    Article  Google Scholar 

  8. Lieu HD, Shryock JC, von Mering GO, Gordi T, Blackburn B, Olmsted AW, et al. Regadenoson, a selective A2A adenosine receptor agonist, causes dose-dependent increases in coronary blood flow velocity in humans. J Nuc Cardiol 2007;14:514-20

    Article  Google Scholar 

  9. Zhao G, Messina E, Xu X, Ochoa M, Sun HL, Leung K, et al. Caffeine attenuates the duration of coronary vasodilation and changes in hemodynamics induced by regadenoson (CVT-3146), a novel adenosine A2A receptor agonist. J Cardiovasc Pharmacol 2007;49(6):369-75

    Article  CAS  PubMed  Google Scholar 

  10. Gaemperli O, Schepis T, Koepfli P, Siegrist PT, Fleischman S, Nguyen P, et al. Interaction of caffeine with regadenoson-induced hyperemic myocardial blood flow as measured by positron emission tomography a randomized, double-blind, placebo-controlled crossover trial. J Am Coll Cardiol 2008;51:328-9

    Article  PubMed  Google Scholar 

  11. Samady H, Wackers FJ, Joska TM, Zaret BL, Jain D. Pharmacologic stress perfusion imaging with adenosine: Role of simultaneous low-level treadmill exercise. J Nuc Card 2002;9(2):188-96

    Article  Google Scholar 

  12. Holly TA, Satran A, Bromet DS, Mieres JH, Frey MJ, Elliott MD, et al. The impact of adjunctive adenosine infusion during exercise myocardial perfusion imaging: Results of the Both Exercise and Adenosine Stress Test (BEAST) trial. J Nuc Card 2003;10(3):291-6

    Article  Google Scholar 

  13. Thomas GS, Thompson RC, Miyamoto MI, Ip TK, Rice DL, Milikien D, et al. The RegEx trial: A randomized, double-blind, placebo- and active- controlled pilot study combining regadenoson, a selective A2A adenosine agonist, with low-level exercise, in patients undergoing myocardial perfusion imaging. J Nuc Card 2009;16(1):63-72

    Article  Google Scholar 

  14. Leaker BR, O’Connor B, Hansel TT, Barnes PJ, Meng L, Mathur VS, et al. Safety of regadenoson, and adenosine A2A agonist for myocardial perfusion imaging, in mild asthma patients: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):329-36

    Article  Google Scholar 

  15. Thomas GS, Tammelin BR, Schiffman GL. Safety of regadenoson, a selective A2A agonist, in patients with chronic obstructive pulmonary disease: A randomized, double-blind, placebo-controlled trial. J Nuc Card 2008;15(3):319-28

    Article  Google Scholar 

  16. Gordi T, Blackburn B, Lieu H. Regadenoson pharmacokinetics and tolerability in subjects with impaired renal function. J Clin Pharmacol 2007;47:825-33

    Article  CAS  PubMed  Google Scholar 

  17. Laighold S, Druz R. Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis. J Nuc Card 2009;16:478-80

    Article  Google Scholar 

  18. Al Jaroudi W, Hermann D, Hage F. Safety of Regadenoson in patients with End-Stage Renal Disease. Am J Cardiol 2010;105:133-5

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, RI, USA

    Anthony S. Gemignani MD & Brian G. Abbott MD

Authors
  1. Anthony S. Gemignani MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian G. Abbott MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brian G. Abbott MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gemignani, A.S., Abbott, B.G. The emerging role of the selective A2A agonist in pharmacologic stress testing. J. Nucl. Cardiol. 17, 494–497 (2010). https://doi.org/10.1007/s12350-010-9211-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12350-010-9211-9

Keywords

Search

Navigation